Description du projet
Un dispositif microfluidique d’ingénierie tissulaire pour le développement de médicaments
Les cultures cellulaires 3D pour la recherche médicale et la médecine régénérative sont essentielles pour des innovations médicales plus précises et éthiques. Les modèles 3D sans échafaudage issus de l’ingénierie tissulaire qui reproduisent les caractéristiques fonctionnelles des tissus natifs soutiennent la recherche de biomarqueurs, le développement de médicaments et les études de toxicologie tout en offrant une alternative à l’utilisation des animaux dans les tests et la recherche de médicaments. Financé par le programme Actions Marie Skłodowska-Curie, le projet SMD-SPH développe un système microphysiologique comprenant un modèle de culture cellulaire 3D avec perfusion contrôlable pour un contact continu avec des facteurs de croissance, dans le but de créer un tissu natif fonctionnel et de surveiller les paramètres physiologiques essentiels. Pour la première fois, des cellules souches dérivées du tissu adipeux humain seront utilisées pour construire le tissu adipeux en tant que système microphysiologique évolutif.
Objectif
In regenerative medicine, in vitro tissue engineering products (3D cell cultures) for in vivo therapy are critical for more accurate and more humane medical innovation. Tissue engineered scaffold-free 3D models that exhibit functional hallmarks of native tissues improve our search for biomarkers, drug testing/development and toxicology with more accurate models, while supporting the development of alternative methods to animal use in drug testing, as stated by the Directive (2010/63/EU) established the European Centre for the validation of alternative methods (ECVAM). To replace animal testing, it is important to develop microphysiological systems and ‘body-on-chip’ approaches that allow to account for organ-to-organ interactions in vitro, at a reasonable cost. Yet, most current bioreactors are expensive, designed for organ transplant (thus focused on a single organ) and poorly designed for miniaturization and scale-up. In SMD-SPH, we will develop a microphysiological systems with the following design requirement: a 3D cell culture model, with a continuous and controllable perfusion system for continuous contact with morphogens (growth factors) to obtain a functional native tissue and monitoring crucial parameters of cell physiology, compatible with scale-up manufacturing. To the best of our knowledge, it is the first time in scientific literature that human adipose tissue-derived stem cells are used to build human white adipose tissue in a novel and scalable microphysiological system. This project meets the convergence of microfluidics and scaffold-free 3D culture models offering a reliable alternative for drug and toxicology assays, besides offer a scalable and reproductible system for future integration into a human-on-a-chip and high-troughput assays. Once an initial prototype is obtained, we will start dissemination to stakeholders and seek early adopters, cosmetic industries.
Champ scientifique
- natural sciencesphysical sciencesclassical mechanicsfluid mechanicsmicrofluidics
- medical and health sciencesmedical biotechnologytissue engineering
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- engineering and technologyother engineering and technologiesmicrotechnologyorgan on a chip
- medical and health sciencesbasic medicinetoxicology
Mots‑clés
Programme(s)
Régime de financement
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinateur
75015 Paris
France
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.